$PRTX Announces Presentation of Preclinical Data


Protalex Announces Presentation of Preclinical Data with PRTX-100 Supporting Treatment of Immune Thrombocytopenia at the American Society of Hematology 57th Annual Meeting and Exposition

Protalex, Inc. (PRTX), a clinical-stage biopharmaceutical company, today announced that an abstract highlighting preclinical results from a study of Staphylococcal protein A (PRTX-100) for the treatment of Immune Thrombocytopenia (ITP) will be presented at the upcoming American Society of Hematology (ASH) 57th Annual Meeting and Exposition being held in Orlando, Florida from December 5-8, 2015. The abstract is available on the ASH website athttp://www.hematology.org and on the Company’s website at www.protalex.com.

The poster will be available for viewing as follows:

Poster Title:

“Successful Treatment of Thrombocytopenia with Staphylococcal Protein A (PRTX-100) in a Murine Model of Immune Thrombocytopenia (ITP)”
Session Name: Disorders of Platelet Number or Function Program
Poster Presentation Time: Saturday, December 5, 2015: 5:30 p.m. -7:30 p.m. (Eastern time)
Location: Exhibit Hall A, Level 2
Presentation Number: 1045
Presenter: John W. Semple, Ph.D., St. Michael’s Hospital, Toronto, Canada

About PRTX-100

PRTX-100, a new generation immunomodulatory therapy, is a highly purified form of SpA, an immunomodulatory protein known to modify aspects of the human immune system. PRTX-100 has the ability, at very low concentrations, to bind to human B-lymphocytes and macrophages and to modulate immune processes. The safety, tolerability and pharmacokinetics of PRTX-100 have been characterized in five clinical studies and was recently granted Orphan Drug Designation in the U.S. and Europe in the treatment of ITP. In two Phase 1b clinical trials in adult patients with active Rheumatoid Arthritis (RA), PRTX-100 was generally safe and well tolerated at all dose levels, and at certain higher doses, more patients showed improvement in measures of RA disease activity than did patients at the lower dose or placebo cohorts. PRTX-100 is given as a short intravenous infusion.

About Protalex, Inc.

Protalex, Inc. is a clinical-stage biopharmaceutical company focused on the development of a class of drugs for treating autoimmune and inflammatory diseases including RA and Immune Thrombocytopenia (ITP). In the U.S., Protalex has open IND’s in RA and ITP. Please visit Protalex’s website at www.protalex.com to learn more about Protalex and its lead product, PRTX-100.

Forward-Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company’s actual operating or clinical results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “believes,” “belief,” “expects,” “expect,” “intends,” “intend,” “anticipate,” “anticipates,” “plans,” “plan,” to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with Securities and Exchange Commission.

Anne Marie Fields, 212-838-3777
[email protected]


Please enter your comment!
Please enter your name here